https://www.selleckchem.com/pr....oducts/SB-743921.htm
8-55.1) was achieved with the median follow-up duration of 12.0 months (range, 8.4-16.1). Median PFS and OS were 5.9 months (95% CI 1.1-11.9) and 15.4 months (95% CI 11.1-not reached), respectively. Treatment-related adverse events (AEs) of any grade were reported in 16 patients; the most common AEs were pruritus (n = 5), pneumonitis (n = 4), and rash (n = 4). Treatment was discontinued in two patients due to AEs of grade ≥ 3. Durvalumab and tremelimumab demonstrated clinical benefit with a prolonged survival and manageable toxicity p
Like
Comment
Share
